BBIO
BridgeBio Pharma, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +23.1% ·
share flow -0.5% ·
net new positions +18.8%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 56.87K | $3.73M | n/a | n/a |
| Q2 2026 | 134 | +3 | 120.77M | $8.70B | +10 | −6 |
| Q1 2026 | 133 | +3 | 129.51M | $9.40B | +8 | −6 |
| Q4 2025 | 129 | +2 | 135.35M | $9.88B | +4 | −1 |
| Q3 2025 | 19 | -1 | 71.67M | $3.72B | n/a | −2 |
| Q2 2025 | 18 | -1 | 70.97M | $3.06B | +1 | −2 |
| Q1 2025 | 16 | +3 | 40.50M | $1.40B | +3 | n/a |
| Q4 2024 | 13 | 0 | 40.68M | $1.12B | +1 | −1 |
| Q3 2024 | 12 | -1 | 35.94M | $914.95M | n/a | −1 |
| Q2 2024 | 13 | n/a | 36.42M | $922.50M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 22.06M | -12.2% | $762.45M | 2.4% | ▼ Trim | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 5.75M | -7.0% | $198.76M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 3.50M | +2.5% | $121.12M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 2.93M | +133.5% | $101.33M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 1.24M | +16.8% | $43.04M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.16M | +17.5% | $40.27M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | PRIMECAP Management ✦ | 913.20K | -0.2% | $31.57M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 843.32K | +253.5% | $29.15M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 516.55K | +91.3% | $17.86M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Duquesne Family Office ✦ | 438.05K | New | $15.14M | 0.5% | New | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 421.86K | -49.0% | $14.58M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 239.92K | +116.0% | $8.29M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 13 | Point72 Asset Management ✦ | 198.78K | New | $6.87M | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 134.26K | -40.0% | $4.64M | 0.0% | ▼ Trim | 4 | SEC ↗ ×5 |
| 15 | D. E. Shaw & Co. ✦ | 83.15K | New | $2.87M | 0.0% | New | 1 | SEC ↗ ×2 |
| 16 | Wellington Management ✦ | 60.01K | -7.4% | $2.07M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Duquesne Family Office | $15.14M | 0.5% |
| Point72 Asset Management | $6.87M | 0.0% |
| D. E. Shaw & Co. | $2.87M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 15.30K shares, $1,136 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.28K sh · $88,980
Officer, Director · 8.72K sh · $601,868
Officer, Director · 1.80K sh · $152,436
Officer, Director · 100 sh · $8,565
Officer, Director · 8.10K sh · $679,256
Officer, Director · 1.90K sh · $154,184
Officer, Director · 17.28K sh · $1.42M
Officer, Director · 14.60K sh · $1.21M
Officer, Director · 1.20K sh · $100,444
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
4.2% of class · View original SEC filing ↗
5.0% of class · View original SEC filing ↗